Bon usage des antidépresseurs ISRS durant la grossesse--le défi de l'évaluation de la balance bénéfice-risque [SSRI antidepressant use during pregnancy and the assessment of the risk-benefit ratio].

Détails

Ressource 1Demande d'une copie Sous embargo indéterminé.
Etat: Public
Version: de l'auteur
ID Serval
serval:BIB_C18A424B9682
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Bon usage des antidépresseurs ISRS durant la grossesse--le défi de l'évaluation de la balance bénéfice-risque [SSRI antidepressant use during pregnancy and the assessment of the risk-benefit ratio].
Périodique
Revue Médicale Suisse
Auteur(s)
Weisskopf E., Fumeaux C.J., Bickle Graz M., Harari M.M., Epiney M., Tolsa C.B., Rouiller S., Tolsa J.F., Eap C.B., Vial Y., Csajka C., Panchaud A.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
2016
Peer-reviewed
Oui
Volume
12
Numéro
510
Pages
561-566
Langue
français
Notes
Publication types: English Abstract ; Journal ArticlePublication Status: ppublish
Résumé
Studies report that between 6 and 13% of women experience symptoms of depression during pregnancy and the postpartum period. The abundant data available make selective serotonin reuptake inhibitors (SSRIs) the first line treatment in pregnancy when a pharmacological treatment is required. Risks associated with the use of SSRIs during pregnancy are limited (moderate effect size) and are often not distinguishable from those inherent to the mother's disease. Yet, several questions regarding the SSRI safety profile for the unborn child are still under debate or require additional epidemiological data. The decision of SSRI use during pregnancy needs an individual evaluation of the risk-benefit balance.
Mots-clé
Antidepressive Agents/adverse effects, Antidepressive Agents/therapeutic use, Depressive Disorder/complications, Depressive Disorder/drug therapy, Female, Humans, Practice Patterns, Physicians', Pregnancy, Pregnancy Complications/chemically induced, Pregnancy Complications/drug therapy, Risk Assessment, Serotonin Uptake Inhibitors/adverse effects, Serotonin Uptake Inhibitors/therapeutic use
Pubmed
Création de la notice
13/06/2016 12:53
Dernière modification de la notice
20/08/2019 15:36
Données d'usage